SES
22.2.2024 14:26:26 CET | Business Wire | Press release
The Luxembourg Directorate of Defence (DoD) procured two ground stations following a competitive call for tender to enable the Luxembourg Army to improve its resilience by accessing secure satellite communications services, the DoD, SES and HITEC Luxembourg said today.
The ground stations, which will be installed at the Luxembourg Army’s Military Centre in Diekirch, will be used for Luxembourg’s GovSat-1 satellite services in X- and Military Ka-band frequencies, as well as for the Wideband Global Satcom (WGS) system, the backbone of the satellite communications capability of the U.S. DoD.
The addition of the two new ground stations reinforce resiliency and augment the existing Luxembourg Army satcom infrastructure already built by SES and HITEC Luxembourg 10 years ago, bringing the total number of dedicated antennas to four. The new ground stations unlock the strong potential to scale and add interoperability with the NATO partner systems, in line with the country’s defence strategy for the years to come.
Yuriko Backes, Luxembourg Minister of Defence: “Access to secure satellite communications has always been among the priorities and strengths of Luxembourg, allowing the country to reinforce defence capabilities, as well as enabling fulfillment of Luxembourg’s commitments towards the EU and NATO. To keep the upper technological edge, we will continue to leverage Luxembourg’s globally-renowned expertise in the space sector, to increase our resilience, including that of our armed forces.”
“It is an honour for SES to help strengthen the Luxembourg Government’s defence pillar by adding resiliency to its secure satcom,” said Adel Al-Saleh, CEO of SES. “Following the successful implementation of the initial ground stations by the Luxembourg Army, we are delighted to extend its communications infrastructure that leverages Luxembourg’s GovSat-1 and enhances interoperability with the partner systems.”
“We are proud to be part of the project and once again join efforts with SES to help augment Luxembourg’s defence capabilities with resilient and proven technology,” said Philippe Osch, CEO of HITEC Luxembourg. “The ground terminals to be supplied for the Luxembourg Army’s satcom infrastructure are a source of particular pride for us as they combine the latest technological innovations and a track-record of superior “Made in Luxembourg” quality.”
Follow us on:
Twitter | Facebook | YouTube | LinkedIn | Instagram
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless data connectivity services around the world. As a leader in global content connectivity solutions, SES owns and operates the world’s only geosynchronous orbit and medium earth orbit (GEO-MEO) constellation of satellites with the unique combination of global coverage and high performance. By leveraging its vast and intelligent, cloud-enabled network, SES delivers high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 6,400 channels, reaching 369 million households, delivering managed media services for both linear and non-linear content. The company is headquartered in Luxembourg and listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com
About HITEC Luxembourg
HITEC Luxembourg S.A., a 100%-owned Luxembourg company, has developed its business activities in the field of innovative and quality products and services.
HITEC offers high technology solutions covering different business areas: satellite ground segment; specific and standard equipment for testing and measuring of physical properties; traffic management; mission critical; engineering; consulting; software & ICT development and project management. HITEC serves private and public sector customers at a national and international level.
In our daily commitment, know-how, creativity, quality and perseverance are an integral part of HITECs’ undertaking. Enthusiasm for technology and innovation and a dedication to life-long-learning are core elements of our company culture, reflected by our highly qualified and motivated staff.
HITEC is ISO 9001, ISO 14001, ISO 45001 and AQAP 2110 certified and has several labels, such as “SuperDrecksKëscht fir Betriber“ (ISO 14024:2000 Standard), “Entreprise Socialement Responsable”, delivered by the indr, Responsibility Europe, Made in Luxembourg (for most of the products & services) and is signatory of the IMS Diversity Charter and the “Pacte National – Entreprises et Droits de l’Homme Luxembourg”. HITECs’ motto: market-oriented, client-centric and technology driven.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222299678/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom